LIBOCE-TRIO-1
Description_Effects
LIBOCE-TRIO-1 is a combination antidiabetic medication that contains Glimepiride, Metformin, and Voglibose. This triple-drug formulation is designed to provide comprehensive blood sugar control in patients with type 2 diabetes mellitus, especially those who do not achieve adequate glycemic control with diet, exercise, and single or dual drug therapy. Glimepiride is a sulfonylurea that works by stimulating the pancreas to release more insulin, helping lower blood sugar levels. Metformin is a biguanide that reduces glucose production in the liver, decreases intestinal glucose absorption, and improves the body's sensitivity to insulin. Voglibose is an alpha-glucosidase inhibitor that delays the digestion and absorption of carbohydrates in the small intestine, helping to control postprandial (after-meal) blood glucose spikes. Together, these three agents work through complementary mechanisms to effectively manage blood sugar throughout the day—before and after meals. LIBOCE-TRIO-1 not only helps in achieving better glycemic control but also minimizes the risk of diabetes-related complications when used as part of a comprehensive diabetes management plan that includes a balanced diet and regular physical activity. This medicine should be taken as prescribed by a healthcare professional. Regular monitoring of blood sugar levels is essential for safe and effective diabetes management.
